LY3848575
DrugAdministered SC
NCT Number: NCT06568042
The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee.
Participation may last up to 30 weeks including screening.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Med Trust Research, Courtice, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered SC
Administered SC
Time frame: Baseline, Week 12
Time frame: Baseline, Week 12
Time frame: Baseline, Week 12
Time frame: Baseline, Week 12
Time frame: Baseline, Week 12
Time frame: Baseline, Week 12
Time frame: Baseline, Week 12
Time frame: Baseline, Week 12
Time frame: Week 12
Time frame: Baseline up to Week 12
Time frame: Baseline up to Week 12
Eli Lilly and Company
Industry
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05935956
Chemotherapy-induced Peripheral Neuropathy, Nervous System Diseases
Winston-Salem, North Carolina, United States
View Trial DetailsNCT05802511
Nervous System Diseases, Neuralgia
Messina, Italy
View Trial DetailsNCT01037088
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Sacramento, California, United States
View Trial DetailsNCT02065349
Nervous System Diseases, Neuralgia
Choceň, Czechia
View Trial Details